Arena Hedges, Shorts And Retail Investors - Oh My [View article]
When Arena was driven down sub-$1.75 a share I bought with the conviction that Lorcaserin--as Belviq was known at time-- would become a blockbuster. If I had followed your strategy of hedging my expectations I would have been shorn of my shares a long time ago. Retail investors aren't as dumb as you suggest.......it is the traders who act on (irrational) emotional impulse.
Trinity Place, A Bankrupt Xanadu, And Changing Leadership [View article]
Thanks for your information and perspective. I trust the board is well aware that Trinity is a prize, that the stakes are high, and they better not screw it up. Ettenger may be incentivized to get this one right, after his failed tenure at Mills.
I got burned by the rootkit problems too and Sony is going to keep falling until the company is broken up, imo.
The premise of the article is solid, however. If not Sony, what then? My suggestion would be Eisai (ESALY), a first class pharmaceutical company with strength in gastrointestinal products that are vital. Plus, by the end of this year, Eisai should be profiting mightily from partner Arena's weight loss drug. With a pharmaceutical company you wont have the cost of raw material problem incurred by a weaker Yen.
Disclosure: I own ARNA, not ESALY, but only because there is no options market in Eisai.
C'mon people, there must be some other Japanese companies that will benefit from a weaker yen.
A Fact Based Analysis Of Galena's NeuVax [View article]
Thanks again Sasquach. I'm wondering if you would share your insight--as a former biotech researcher--into other opportunities? Are there any other compounds that strike your fancy?
A Fact Based Analysis Of Galena's NeuVax [View article]
Thanks Sasquach. Maybe this is the reason why we were able to acquire the vaccine from Apthera for "only" $6mm--it was cognitive dissonance among biotech scientists (and poseur biologists like Propthink and Adam F.). I think it is safe to say that immune studies will continue to surprise.
There must be some kind of mechanism at work that keeps some breast cancer survivors node negative while others remain, or become, node positive. If Neuvax pushes the NP's to the disease free column (until nature smartens up) it will be a godsend.
A Fact Based Analysis Of Galena's NeuVax [View article]
"The immune system can become tolerized against large quantities of antigen. More is not always better (contrary to the argument)."
This torpedoes, once and for all, the bear thesis (first advanced by Adam F.) that it is illogical, for NeuVax to be less effective for HER +3 node positive patients.
Arena Hedges, Shorts And Retail Investors - Oh My [View article]
Coach Results - The Good, The Bad, And The Ugly [View article]
Trinity Place, A Bankrupt Xanadu, And Changing Leadership [View article]
Forget Herbalife; Blyth Is The Real MLM Steal [View article]
How about, "I/he/she was Ackattacked"
Buy Sony Hand Over Fist [View article]
....and Apple is going to get crushed by Google/Intel.
Buy Sony Hand Over Fist [View article]
The premise of the article is solid, however. If not Sony, what then? My suggestion would be Eisai (ESALY), a first class pharmaceutical company with strength in gastrointestinal products that are vital. Plus, by the end of this year, Eisai should be profiting mightily from partner Arena's weight loss drug. With a pharmaceutical company you wont have the cost of raw material problem incurred by a weaker Yen.
Disclosure: I own ARNA, not ESALY, but only because there is no options market in Eisai.
C'mon people, there must be some other Japanese companies that will benefit from a weaker yen.
A Fact Based Analysis Of Galena's NeuVax [View article]
(Immunocellular (IMUC) has caught my eye).
A Fact Based Analysis Of Galena's NeuVax [View article]
There must be some kind of mechanism at work that keeps some breast cancer survivors node negative while others remain, or become, node positive. If Neuvax pushes the NP's to the disease free column (until nature smartens up) it will be a godsend.
Hot Biotechs And Possible Shorting Opportunities [View article]
A Fact Based Analysis Of Galena's NeuVax [View article]
This torpedoes, once and for all, the bear thesis (first advanced by Adam F.) that it is illogical, for NeuVax to be less effective for HER +3 node positive patients.
Great work, Rich, kudos, and thankyou!!!!!
The Other Side Of Galena Biopharma [View article]
It was your lab. Your research was outstanding, wonderful.
The Other Side Of Galena Biopharma [View article]
No......No he never corrected, never recanted. Financial analysts never admit their lies or half-lies.
Arena Pharmaceuticals Outlines Its Path To Profitability [View article]
The Other Side Of Galena Biopharma [View article]
I dont think so, he misread AF's motivations in previous threads.
The Other Side Of Galena Biopharma [View article]
Patents for the Neuvax mechanism are held by Dr. Peoples.